drugset / Trial / NCT04682119
A Safety Study of LY3526318 in Healthy Participants
RandomizedSequentialDouble-blindBasic science
Summary
The main purpose of this study is to learn more about how the drug is absorbed in to the blood stream and how it is eliminated from the body. The safety and tolerability of LY3526318 will also be evaluated when given by mouth either by single or multiple doses to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 44 days and Part B will last up to 50 days, including screening and follow-up.
Timeline
- Start
- 2020-12-29
- Primary completion
- 2021-04-21
- Completion
- 2021-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3526318 | Unknown | 100 mg | Oral |
| Subject | LY3526318 | Unknown | 250 mg | Oral |
Indications
No indication recorded.